Verrica Pharmaceuticals Inc. Finance Lease, Right-of-Use Asset, after Accumulated Amortization
Verrica Pharmaceuticals Inc. (VRCA) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $1.47 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2026-08-06
- 2026-06-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $1.47M.
- 2026-03-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $1.01M.
- 2025-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $1.11M.
- 2025-09-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $1.05M.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization |
|---|---|
| 2026-06-30 | $1.47M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $1.01M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $1.11M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $1.05M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $945.00K 10-Q · filed 2025-08-12 |
| 2025-03-31 | $1.03M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $1.15M 10-K · filed 2026-03-11 |
| 2024-09-30 | $2.64M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $2.52M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $2.46M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $1.41M 10-K · filed 2025-03-11 |
| 2022-12-31 | $0.00 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |